PALVELLA THERAPEUTICS, INC
NASDAQ: PVLA (Palvella Therapeutics, Inc.)
Kemas kini terakhir: semalam, 9:47AM142.85
-2.92 (-2.00%)
| Penutupan Terdahulu | 145.77 |
| Jumlah Dagangan | 192,670 |
| Purata Dagangan (3B) | 240,407 |
| Modal Pasaran | 2,088,246,656 |
| Harga / Buku (P/B) | 10.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| EPS Cair (TTM) | -5.53 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.84% |
| Nisbah Semasa (MRQ) | 16.01 |
| Aliran Tunai Operasi (OCF TTM) | -43.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.99 M |
| Pulangan Atas Aset (ROA TTM) | -28.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -63.39% |
Sentimen Berita
-
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
3 hari lalu, 6:30AM
-
Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
05 Nov, 5:16PM
-
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
05 Nov, 4:14PM
AISkor Stockmoo
| Nilai 30% | 0.0 |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | 1.3 |
| Tiada aliran jelas sepanjang tahun lalu. Agak di bawah paras tertinggi 52 minggu. info | |
| Aliran menaik: harga di atas purata bergeraknya, dan purata itu sedang meningkat. Harga hampir dengan purata itu. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Sentimen 20% | 0.5 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini kebanyakannya positif. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 1.6 |
| Tiada belian atau jualan bersih orang dalam yang jelas. info | |
| Institusi bersih +8.08% daripada saham dalam pemfailan 13F terkini: 120 pemegang menambah, 80 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +13.5% dari 31 Aug hingga 30 Oct 2026, 11.5 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham turun naik. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Corak pembalikan menaik baru-baru ini: Tukul terbalik, Engulfing menaik. info | |
| Di atas garis aliran jangka sederhana. info | |
| Harga tinggi berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek semakin lemah. info | |
| Harga hampir dengan paras sokongan. info | |
| Skor Akhir | 0.85 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Palvella Therapeutics, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
| GPCR | 1 B | - | - | 1.01 | -0.8 |
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 11.05% |
| % Dimiliki oleh Institusi | 105.08% |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MARTINI JEFFREY S | - | 166.33 | -12,500 | -2,079,063 |
| Jumlah Keseluruhan Kuantiti Bersih | -12,500 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,079,063 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 166.33 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MARTINI JEFFREY S | Pegawai | 11 Nov 2026 | Jual automatik (-) | 6,250 | 163.94 | 1,024,625 |
| MARTINI JEFFREY S | Pegawai | 11 Nov 2026 | Pelaksanaan pilihan | 6,250 | - | - |
| MARTINI JEFFREY S | Pegawai | 10 Nov 2026 | Jual automatik (-) | 6,250 | 168.71 | 1,054,438 |
| MARTINI JEFFREY S | Pegawai | 10 Nov 2026 | Pelaksanaan pilihan | 6,250 | - | - |
Institusi
Pemilikan institusi: 103.74%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 120 | 2,170,153 |
| Berkurang | 80 | 1,570,653 |
| Baharu | 37 | 905,228 |
| Dijual habis | 27 | 292,038 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 2,601,661 | 11.5 |
| 15 Oct 2026 | 2,407,482 | 9.8 |
| 30 Sep 2026 | 2,524,140 | 10.7 |
| 15 Sep 2026 | 2,325,699 | 12.8 |
| 31 Aug 2026 | 2,291,288 | 11.1 |
| 14 Aug 2026 | 2,149,544 | 12.8 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Nov 2026 | Yahoo Finance |
Palvella Therapeutics (PVLA) Stock Looks Above Fair Value After 51% Gain
Palvella Therapeutics has logged a strong 51.3% share price gain over the past year, which puts fresh attention on whether that move lines up with what its balance sheet actually supports. With traders also reacting to new product news, the question is how firmly the current valuation rests on… |
| 19 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
EMPD is a serious, rare, and life-threatening genital and perianal skin cancer QTORIN™ docetaxel builds on human clinical evidence of I.V. docetaxel in EMPD, with the potential to shift the treatment paradigm to first-line, localized topical therapy QTORIN™ docetaxel has the potential to be the… |
| 19 Nov 2026 | Yahoo Finance |
Is Palvella Therapeutics (PVLA) Undervalued On Its New QTORIN Webcast Plans?
Palvella Therapeutics (PVLA) is back in focus after the company scheduled a November 19 webcast to introduce a new QTORIN program, the third drug candidate from its QTORIN platform for rare skin conditions. Palvella Therapeutics shares closed at $146.58, with a 1-day share price return of 1.54%.… |
| 18 Nov 2026 | Yahoo Finance |
Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program
Third product candidate from Palvella’s QTORIN™ platform to be announced Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET WAYNE, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a… |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
Palvella Therapeutics Inc (PVLA) advances its Qtorin rapamycin NDA toward a February 2027 PDUFA date while funding a standalone U.S. launch and a deep pipeline of first-in-disease programs. |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Palvella Therapeutics, Inc.'s Q3 2026 earnings call… |
| 05 Nov 2026 | Yahoo Finance |
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential U.S. launch of QTORIN rapamycin after the Food and Drug Administration accepted its application for the treatment of microcystic lymphatic malformations and granted it Priority Review. The FDA set a target action date of February 28,… |
| 05 Nov 2026 | Yahoo Finance |
Palvella (PVLA) Q3 2026 Earnings Call Transcript
QTORIN rapamycin wins priority FDA review for a rare vascular disease. |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics: Q3 Earnings Snapshot
(AP) — Palvella Therapeutics, Inc. (PVLA) on Thursday reported a loss of $24… |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 QTORIN™ Rapamycin Could Become the First FDA-Approved Therapy for Microcystic Lymphatic Malformations, a Serious, Rare Lifelong Disease… |
| 03 Nov 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 29 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 28 Oct 2026 | Yahoo Finance |
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and adults in the U.S. Phase 3 SELVA study achieved highly statistically significant results across all… |
| 25 Oct 2026 | Yahoo Finance |
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said during a Chardan investor session. Korenberg said the company has expanded from deve… |
| 24 Oct 2026 | Yahoo Finance |
What Does Palvella Therapeutics (PVLA) NDA Progress Mean After Its Phase 3 Data?
Palvella Therapeutics (NasdaqGM:PVLA) reported positive Phase 3 SELVA trial results for QTORIN rapamycin in microcystic lymphatic malformations. The company has completed an FDA New Drug Application for QTORIN rapamycin following the SELVA efficacy and safety findings. Management also released new… |
| 22 Oct 2026 | Yahoo Finance |
Ligand to Host Investor Day on December 8, 2026
JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY… |
| 21 Oct 2026 | Yahoo Finance |
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering. |
| 15 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in… |
| 13 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 12 Oct 2026 | Yahoo Finance |
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours Comprehensive Real-World… |
| 28 Sep 2026 | Yahoo Finance |
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric… |
| 09 Sep 2026 | Yahoo Finance |
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and… |
| 02 Sep 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are… |
| 31 Aug 2026 | Yahoo Finance |
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S. FDA previously granted Breakthrough Therapy and Fast Track… |
| Papar semua | ||
Isyarat Terkini corak lilin dan silang EMA
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |